Navigating the Evolving Treatment Landscape of Metastatic Renal Cell Carcinoma

Program Description

Renal cell carcinoma (RCC) comprises about 85% of kidney tumors, with approximately 70% of these cases being clear cell RCC. RCC is often resistant to traditional chemotherapy and radiation therapy, resulting in a 5-year relative survival of 15.3% for the 15% of individuals with metastatic disease at the time of diagnosis. Traditionally, treatment approaches to RCC have included cytokines, mammalian target of rapamycin inhibitors, antibodies targeting vascular endothelial growth factor (VEGF) receptors, and VEGF tyrosine kinase inhibitors; however, the use of combination therapies including immune checkpoint inhibitors has emerged as a promising approach, harnessing the benefits of both targeted therapies and immunotherapies. Managed care pharmacists can personalize treatment strategies for patients through proper treatment selection, monitoring, and toxicity management. This activity will further educate pharmacists on available treatments, guideline recommendations, and strategies for improving adherence and managing the cost of care to ensure the safe and effective delivery of treatment to patients with relapsed or refractory metastatic RCC.

Target Audience: Managed Care Pharmacist, Oncology Pharmacist

Type of Activity: Application
Release date: December 1, 2023
Expiration date: December 1, 2024

Time to complete activity: 2.0 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Analyze the influence of novel pharmacologic agents and their pharmacokinetic properties on the personalized treatment strategy for patients with metastatic renal cell carcinoma (mRCC)
• Explore the latest guideline recommendations in the management of advanced and mRCC to inform evidence-based treatment decisions
• Employ value-based approaches to enhance the cost-effectiveness, safety profile, and overall quality of life for patients with mRCC